IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence
Retrieved on:
Tuesday, March 29, 2022
Infectious Diseases, Biotechnology, Health, TSX Venture Exchange, Company, SPA, Therapy, Drug development, Epitope, Multiomics, NASDAQ, DNA, Transaction, Forward-looking statement, Multimedia, Non-competitive inhibition, Board, Biotechnology, Research, Genomics, Precision medicine, RNA, Data analysis, Language, Employment, TSX, Metabolomics, Software, NLP, Biology, Technology, Database, Acquisition, Time, Mass spectrometry, Algorithm, Phrase, News, Food and Drug Administration Amendments Act of 2007, Proteomics, VWAP, AI, Protein, Policy, Antibody, Fine chemical, Medical imaging, Risk management, Life insurance, Online gambling, Security (finance), Property management, Audit, Real estate, IPA, IMMUNOPRECISE ANTIBODIES LTD., BIOSTRAND BV, BIOKEY BV, BIOCLUE BV
BioStrand offers a revolutionary, cloud-based solution to perform multi-omics research faster and more accurately, with more effective data analysis.
Key Points:
- BioStrand offers a revolutionary, cloud-based solution to perform multi-omics research faster and more accurately, with more effective data analysis.
- The acquisition enhances IPAs position as a leader in the field of biotherapeutics - BioStrands software and AI capabilities complement every sector of IPAs business.
- BioStrands semantically driven natural language process (NLP) approach makes omics data research truly effective and differentiates IPAs offerings to provide a powerful and unique opportunity for IPAs clients.
- Total consideration of 20 million, of which 2 million will be paid in cash, subject to adjustments, and 18 million will be paid in equity.